Research Alliance CORP Iv Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have jointly filed a Schedule 13G, reporting beneficial ownership of 5.5% of Research Alliance Corporation IV's Class A Ordinary Shares.
Multiple Biotechnology Value Funds and Mark N. Lampert report a combined beneficial ownership of 6.4% in Research Alliance Corp IV Class A Ordinary Shares.
Commodore Capital LP, along with affiliated entities and individuals, has disclosed beneficial ownership of 5.5% of Research Alliance Corp IV's Class A Ordinary Shares.
Perceptive Advisors LLC, along with affiliated entities, has reported beneficial ownership of 700,000 Class A Ordinary Shares, representing 7.7% of the outstanding shares of Research Alliance Corporation IV.